NOVO NORDISK A/S |
Temps réel estimé
Autres places de cotation
|
Varia. 5j. | Varia. 1 janv. | ||
| 857,3 DKK | -2,44 % |
|
-0,63 % | +22,80 % |
| 12:11 | Scholz promet de soutenir le secteur pharmaceutique en Allemagne alors que Merck investit | RE |
| 24/04 | Mise à jour sectorielle : Les actions du secteur de la santé en baisse en fin d'après-midi | MT |
Métier
- produits de traitement du diabète et de l'obésité (92,6%) ;
- produits de traitement des maladies rares (7,4%) : destinés au traitement de l'hémophilie, des troubles sanguins, des troubles hormonaux, etc.
La répartition géographique du CA est la suivante : Europe-Moyen Orient-Afrique (21,9%), Etats-Unis (54,9%), Amérique du Nord (3,9%), Chine (7,2%) et autres (12,1%).
Nombre d'employés: 63 845
Ventes par activité
| DKK en Millions | 2022 | Poids | 2023 | Poids | Delta |
|---|---|---|---|---|---|
Diabetes and Obesity Care
92,6
%
| 156 412 | 88,4 % | 215 098 | 92,6 % | +37,52 % |
Rare Disease
7,4
%
| 20 542 | 11,6 % | 17 163 | 7,4 % | -16,45 % |
Ventes par région
| DKK en Millions | 2022 | Poids | 2023 | Poids | Delta |
|---|---|---|---|---|---|
United States
54,9
%
| 84 656 | 47,8 % | 127 534 | 54,9 % | +50,65 % |
EMEA
21,9
%
| 44 236 | 25,0 % | 50 867 | 21,9 % | +14,99 % |
Rest of the World
12,1
%
| 25 402 | 14,4 % | 28 078 | 12,1 % | +10,53 % |
China
7,2
%
| 16 209 | 9,2 % | 16 687 | 7,2 % | +2,95 % |
Canada
3,9
%
| 6 451 | 3,6 % | 9 095 | 3,9 % | +40,99 % |
Dirigeants
| Dirigeants | Titre | Age | Depuis |
|---|---|---|---|
| Chief Executive Officer | 58 | 01/01/91 | |
| Director of Finance/CFO | 53 | 01/01/99 | |
Stephen Gough
CTO | Chief Tech/Sci/R&D Officer | - | 01/10/15 |
Marcus Schindler
CTO | Chief Tech/Sci/R&D Officer | 57 | 01/01/18 |
| Chief Operating Officer | 54 | 01/01/92 | |
| Chief Tech/Sci/R&D Officer | 54 | 01/01/99 | |
Daniel Bohsen
IRC | Investor Relations Contact | - | 01/03/20 |
Tania Sabroe
HRO | Human Resources Officer | 47 | 01/01/07 |
| General Counsel | - | - | |
Sergey Manelis
PRN | Corporate Officer/Principal | - | 13/07/20 |
Administrateurs
| Administrateurs | Titre | Age | Depuis |
|---|---|---|---|
Sylvie Grégoire
BRD | Director/Board Member | 63 | 19/03/15 |
Helge Lund
CHM | Chairman | 61 | 23/03/17 |
Martin MacKay
BRD | Director/Board Member | 68 | 01/03/18 |
Laurence Debroux
BRD | Director/Board Member | 54 | 21/03/19 |
Kasim Kutay
BRD | Director/Board Member | 59 | 23/03/17 |
Andreas Fibig
BRD | Director/Board Member | 62 | 01/03/18 |
Henrik Poulsen
BRD | Director/Board Member | 57 | 25/03/21 |
| Director/Board Member | 58 | 01/01/92 | |
| Director/Board Member | 49 | 22/03/18 | |
Thomas Rantzau
BRD | Director/Board Member | 52 | 22/03/18 |
Classe d'actions
| Vote | Nombre | Flottant | Autocontrôle | Flottant Total | |
|---|---|---|---|---|---|
| Action A | 10 | 1 075 000 000 | 0 | 0 | 70,47 % |
| Action B | 1 | 3 435 000 000 | 3 178 045 788 ( 92,52 %) | 51 700 000 ( 1,505 %) |
Participations
| Nom | Actions | % | Valorisation |
|---|---|---|---|
NOVO NORDISK A/S 1,42% | 48 674 207 | 1,42% | 6 223 028 030 $ |
NNIT A/S 17,50% | 4 375 000 | 17,50% | 68 672 756 $ |
INNATE PHARMA 12,14% | 9 817 546 | 12,14% | 23 167 445 $ |
Coordonnées société
Sociétés du groupe
| Nom | Catégorie et Secteur |
|---|---|
NNE A/S
 NNE A/S Engineering & ConstructionIndustrial Services Part of Novo Nordisk A/S, NNE A/S is a Danish company that supplies systems, consultancy and engineering services. The private company is based in Soborg, Denmark. |
Engineering & Construction
|
Novo Nordisk Region Europe A/S
 Novo Nordisk Region Europe A/S Financial ConglomeratesFinance Novo Nordisk Region Europe A/S holds ownership interests in other companies to undertake investment and financing activities. It offers service on an operational basis, including the placement of capital in companies and real estate. The company was founded September 14, 2001 and is headquartered in Bagsvaerd, Denmark. |
Financial Conglomerates
|
Novo Nordisk Health Care AG
 Novo Nordisk Health Care AG Pharmaceuticals: MajorHealth Technology Novo Nordisk Health Care AG engages in the production and distribution of chemical and pharmaceutical products as well as articles for diagnostic and therapeutic applications. It also specializes in the research in and development of products, therapeutic methods, and display techniques primarily used in the chemical, pharmaceutical, and diagnostic fields. The company was founded on August 10, 2000 and is headquartered in Zurich, Switzerland. |
Pharmaceuticals: Major
|
Novo Nordisk India Pvt Ltd.
 Novo Nordisk India Pvt Ltd. Medical/Nursing ServicesHealth Services Part of Novo Nordisk A/S, Novo Nordisk India Pvt Ltd. is a leading healthcare company founded in 1923 and headquartered in Denmark. The private company is based in Bengaluru, India. Novo Nordisk's purpose is to drive change to defeat diabetes and other serious chronic diseases. |
Medical/Nursing Services
|
World Diabetes Foundation
|
Investment Trusts/Mutual Funds
|
Velfærdsfonden for Novo Nordisk A/S
|
Investment Trusts/Mutual Funds
|
Novo Nordisk Finance (Netherlands) BV
|
Finance/Rental/Leasing
|
Secteur
Ventes par activité
Ventes par région
Révisions de BNA
| Varia. 1 janv. | Capi. | |
|---|---|---|
| +22,80 % | 562 Md | |
| +25,61 % | 660 Md | |
| -5,24 % | 358 Md | |
| +16,49 % | 322 Md | |
| +8,28 % | 297 Md | |
| +12,79 % | 219 Md | |
| -9,65 % | 196 Md | |
| +6,39 % | 199 Md | |
| -8,75 % | 149 Md | |
| -5,21 % | 146 Md |
- Bourse
- Actions
- Action NOVO B
- Société Novo Nordisk A/S
